CD13 Antibody (3D8): sc-13536

CD13 Antibody (3D8) is a mouse monoclonal IgG2a kappa light chain antibody that detects CD13 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Anti-CD13 antibody (3D8) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CD13, also known as aminopeptidase N, is a type II transmembrane glycoprotein predominantly expressed on myeloid cells such as monocytes, basophils, eosinophils, neutrophils, and in myeloid leukemias, as well as on certain epithelial cells, fibroblasts, and osteoclasts. CD13 functions as a zinc-binding metalloprotease, playing a crucial role in the digestion of peptides and the inactivation of regulatory peptides like enkephalins, which are important for pain modulation and stress response. CD13 presence on cancer cells has been linked to enhanced invasive capacity and metastatic behavior, making CD13 a potential target for therapeutic intervention. Notably, CD13 expression can be upregulated by basic fibroblast growth factor (bFGF) in human melanoma cells, which activates both the myeloid and epithelial CD13 promoters, highlighting CD13 significance in cancer biology and potential as a biomarker for tumor progression.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD13 Antibody (3D8) References:

1. CD-13 ('gp150'; aminopeptidase-N): co-expression on endothelial and haemopoietic cells with conservation of functional activity.  |  Favaloro, EJ. 1991. Immunol Cell Biol. 69 (Pt 4): 253-60. PMID: 1723966
2. Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies belonging to CD-11b, CD-13 and CD-33.  |  Favaloro, EJ., et al. 1988. Br J Haematol. 69: 163-71. PMID: 2455535
3. CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders.  |  Lu, C., et al. 2020. J Immunol. 204: 3-11. PMID: 31848300
4. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia.  |  He, X., et al. 2020. Blood. 135: 713-723. PMID: 31951650
5. The Role of the Ectopeptidase APN/CD13 in Cancer.  |  Lendeckel, U., et al. 2023. Biomedicines. 11: PMID: 36979703
6. CD13 facilitates immune cell migration and aggravates acute injury but promotes chronic post-stroke recovery.  |  Nguyen, JN., et al. 2023. J Neuroinflammation. 20: 232. PMID: 37817190
7. Human myeloid differentiation antigens identified by monoclonal antibodies: expression on leukemic cells.  |  Bradstock, KF., et al. 1985. Pathology. 17: 392-9. PMID: 3865147
8. Novel paired CD13-negative (MT-50.1) and CD13-positive (MT-50.4) HTLV-1-infected T-cell lines with differential regulatory T cell-like activity.  |  Egawa, Y., et al. 2024. Sci Rep. 14: 12549. PMID: 38822041
9. Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis.  |  Muraoka, S., et al. 2025. Arthritis Rheumatol. 77: 80-91. PMID: 39175116
10. Myeloid progenitor surface antigen identified by monoclonal antibody.  |  Bradstock, KF., et al. 1985. Br J Haematol. 61: 11-20. PMID: 4052321
11. CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated.  |  Favaloro, EJ., et al. 1993. Exp Hematol. 21: 1695-701. PMID: 7902291
12. The hepatobiliary disease marker serum alanine aminopeptidase predominantly comprises an isoform of the haematological myeloid differentiation antigen and leukaemia marker CD-13/gp150.  |  Favaloro, EJ., et al. 1993. Clin Chim Acta. 220: 81-90. PMID: 7904544

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CD13 Antibody (3D8) has 28 citations in a variety of scientific publications.

Primary antibodies like Anti-CD13 Antibody (3D8) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CD13 Antibody (3D8) Specifications

Alternate Product Name: CD13

Product Clone Name: 3D8

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids:

Epitope Target: CD13

Epitope Species: human

Product Reactivity/Detection: myleiod cell CD13

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 28 citations in various scientific publications

Available Conjugates/Forms for CD13 Antibody (3D8): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin